Sodium-glucose cotransporter 2 inhibitors for wild-type transthyretin amyloidosis: Insights from a global database
SGLT2i use was associated with better survival and a lower incidence of clinical heart failure. These findings signal a potential prognostic benefit of SGLT2i in wtATTR that should be explored further.
Authors
- David G. Wilson (ORCID: https://orcid.org/0000-0002-8487-6813)
- Zafraan Zathar (ORCID: https://orcid.org/0000-0003-2495-9884)
Institutions
- Worcestershire Acute Hospitals NHS Trust (GB)
- Dudley Group NHS Foundation Trust (GB)
- University of Birmingham (GB)
Publication Details
- Journal
- American Heart Journal Plus Cardiology Research and Practice
- Published
- 2025-09-24
- DOI
- https://doi.org/10.1016/j.ahjo.2025.100625
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00